News &amp; Updates

Viral shedding lasts 50 days in man with mild COVID-19

A new study reports a case of mild coronavirus disease 2019 (COVID-19) but with an unusually long period of viral shedding, reaching nearly 50 days.

Viral shedding lasts 50 days in man with mild COVID-19

COVID-19 unlikely to be transmitted through tears

02 Apr 2020 by

The transmission of the coronavirus disease 2019 (COVID-19) through tears appears to be unlikely, according to a Singapore study.

COVID-19 unlikely to be transmitted through tears

How COVID-19 has changed our lives

The coronavirus has been spreading at a frantic pace, isolating families and snuffing out lives. As hunger and emotional contagion grip the nations, the hope of a containment also dims. No one has seen this enemy coming – the world has underestimated COVID-19.

How COVID-19 has changed our lives

Ophthalmologists must adopt Infection control measures during COVID-19 outbreak

Ophthalmologists are advised to cooperate with local infection control teams in the implementation of infection control measures that are appropriate for their clinical settings in order to minimize the transmission of coronavirus disease 2019 (COVID-19), suggests a Hong Kong study.

Ophthalmologists must adopt Infection control measures during COVID-19 outbreak

Smoking may worsen COVID-19 severity

Smoking appears to contribute to a more severe COVID-19*, leading to more adverse outcomes and negative disease progression, according to a recent systematic review.

Smoking may worsen COVID-19 severity

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine shows therapeutic potential over an oral antiretroviral therapy (ART) regimen in adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

FDA emergency approval granted for 5-minute SARS-CoV-2 point-of-care test

The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for a molecular point-of-care SARS-CoV-2 test that promises to deliver results in minutes.

FDA emergency approval granted for 5-minute SARS-CoV-2 point-of-care test